↓ Skip to main content

Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain

Overview of attention for article published in Health Economics Review, December 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

policy
1 policy source
twitter
1 X user

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
36 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain
Published in
Health Economics Review, December 2013
DOI 10.1186/2191-1991-3-28
Pubmed ID
Authors

Carlos Crespo, Estela Moreno, Jordi Sierra, Suzan Serip, Marta Rubio

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 36 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 10 28%
Other 6 17%
Student > Doctoral Student 5 14%
Student > Master 4 11%
Student > Ph. D. Student 2 6%
Other 4 11%
Unknown 5 14%
Readers by discipline Count As %
Medicine and Dentistry 8 22%
Economics, Econometrics and Finance 8 22%
Pharmacology, Toxicology and Pharmaceutical Science 5 14%
Business, Management and Accounting 1 3%
Nursing and Health Professions 1 3%
Other 6 17%
Unknown 7 19%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 January 2022.
All research outputs
#7,052,105
of 23,700,294 outputs
Outputs from Health Economics Review
#116
of 452 outputs
Outputs of similar age
#82,620
of 311,029 outputs
Outputs of similar age from Health Economics Review
#2
of 10 outputs
Altmetric has tracked 23,700,294 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 452 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,029 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 8 of them.